ロード中...
Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
Targeted molecular therapy is an effective anticancer strategy. Anti‐EGFR monoclonal antibodies such as cetuximab (CTX) have been approved for the treatment of various malignancies, including colorectal cancer (CRC) with wild‐type KRAS. However, their efficacy in patients with KRAS mutations has not...
保存先:
| 出版年: | Int J Cancer |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5057332/ https://ncbi.nlm.nih.gov/pubmed/26437179 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29881 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|